| |
Migenix to start HCV drug trial in Q2
|
| |
| |
VANCOUVER, British Columbia, Jan. 23 (UPI) -- Migenix said Monday it would launch early in the second quarter of 2006 a trial of hepatitis C drug MX-3253.
The company said it would begin a Phase 2b viral kinetics clinical trial of its first-in-class oral therapy MX-3253 (celgosivir) in patients with chronic hepatitis C virus (HCV).
Migenix said its study of the alpha glucosidase 1 inhibitor is designed to show the drug improves anti-viral activity in treatment-naive HCV patients when celgosivir is used in combination with interferon over a treatment period of up to 28 days.
Migenix said it expected to have the findings in the second half of 2006.
|
|
| |
| |
|
|
|
